Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Boulevard Bio raises $65M in funding led by Deerfield Management to advance its multi-specific antibodies for autoimmune diseases.
PRIVATEAug 13, 2026•about 2 hours ago
Amount Raised
$65 Million
Round Type
Venture - Series Unknown
New YorkBiotechnologyTherapeuticsInvestors
Deerfield Management
Description
Boulevard Bio, a NYC-based precision immunology company, raised $65M in funding. Backers included Deerfield Management and its affiliates. The company intends to use the funds to advance its pipeline of multi-specific antibodies targeting B cell-driven autoimmune diseases, including its lead candidate BLVD101. Led by CEO Mahesh Karande and CMO Neil Solomons, Boulevard Bio focuses on engineered multi-specific antibodies.
Don't miss Boulevard Bio's next move
Get an email the moment Boulevard Bio raises, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech